UCL (UCL) Stock Price & Analysis
UCL (UCL) fell 2.68% to USD 0.4 as of September 9, 2026 at 07:12 UTC, according to Nexqual real-time market data.
UCL last closed at USD 0.41; the session ranged USD 0.39–0.42 on volume of 635,916 shares. Market capitalization is $15.35M, with a 52-week range of USD 0.34–2.81 (NGM). Source: Nexqual, September 9, 2026 at 07:12 UTC.
Key Statistics (as of September 9, 2026 at 07:12 UTC)
| Price | USD 0.4 |
|---|---|
| Change | ▼ 2.68% (down) |
| Previous Close | USD 0.41 |
| Open | USD 0.41 |
| Day Range | USD 0.39 – 0.42 |
| 52-Week Range | USD 0.34 – 2.81 |
| Volume | 635,916 shares |
| Market Cap | $15.35M |
| Exchange | NGM |
Technical Analysis (UCL)
Nexqual's technical model rates UCL "SELL" based on 1 bullish and 5 bearish signals across 127 daily candles, as of September 9, 2026 at 07:12 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 26.34 (oversold) |
| vs SMA50 | Below (USD 0.73) |
| MACD | -0.11 (negative) |
Analyst Ratings (UCL)
Wall Street analysts rate UCL "Strong Buy" based on 1 analysts, with a mean price target of USD 8 (range USD 8–8), per Nexqual as of September 9, 2026 at 07:12 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 1 |
| Mean Target | USD 8 |
| High Target | USD 8 |
| Low Target | USD 8 |
| Buy / Hold / Sell | 1 / 0 / 0 |
Earnings (UCL)
| Revenue Estimate | $20.00M |
|---|
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.08 vs est -0.05 ▼ miss |
| 2026-03-31 | USD -0.09 vs est -0.07 ▼ miss |
| 2025-12-31 | USD -0.08 vs est -0.06 ▼ miss |
| 2025-09-30 | USD 0.24 vs est 0.02 ▲ beat |
Source: Nexqual, September 9, 2026 at 07:12 UTC.
Financials & Fundamentals (UCL)
| Total Revenue | $78.42M |
|---|---|
| Revenue Growth (YoY) | -5.90% |
| Gross Margin | +51.26% |
| Operating Margin | -15.87% |
| Profit Margin | -0.31% |
| ROE | -1.06% |
| Debt / Equity | 59.95 |
| Current Ratio | 1.58 |
| Total Cash | $37.38M |
| Total Debt | $13.79M |
| Free Cash Flow | $-7.15M |
Source: Nexqual, September 9, 2026 at 07:12 UTC.
Financial Health Score (UCL)
Nexqual rates UCL's overall financial health "Weak" across five dimensions, as of September 9, 2026 at 07:12 UTC.
| Growth | Critical — Revenue -11% YoY (annual), sharp decline |
|---|---|
| Profitability | Mixed — Gross margin 51%, operating -16% |
| Balance Sheet | Solid — $37M cash vs $14M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$7M, burning cash |
| Efficiency | Critical — ROE -1%, ROA -4.0% |
Ownership (UCL)
| Insider Ownership | +18.28% |
|---|---|
| Institutional Ownership | +17.20% |
| Shares Outstanding | 25.88M |
| Float | 15.11M |
| Short % of Float | +0.01% |
Source: Nexqual, September 9, 2026 at 07:12 UTC.
Leadership (UCL)
UCL is led by Chaohui Chen (age 56), CEO & Director, per Nexqual as of September 9, 2026 at 07:12 UTC.
| CEO & Director | Chaohui Chen (age 56) |
|---|---|
| Chief Financial Officer | Yimeng Shi (age 51) |
| CTO & Cybersecurity Officer | Zhihui Gong (age 54) |
| Chief Strategy Officer | Wen Gao (age 54) |
Major Backers & Investors (UCL)
Notable institutional backers of UCL include Renaissance Technologies, according to Nexqual as of September 9, 2026 at 07:12 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Renaissance Technologies | 0.14% |
Source: Nexqual, September 9, 2026 at 07:12 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| BR | Broadridge Financial Solutions, | USD 168.62 | ▼ 5.75% |
| UPC | Universe Pharmaceuticals Inc | USD 4.2 | ▼ 3% |
| SKE | Skeena Resources Limited | USD 32.76 | ▼ 1.06% |
| HUIZ | Huize Holding Limited | USD 1.49 | ▲ 3.47% |
| QH | Quhuo Limited | USD 4.02 | ▲ 2% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 9, 2026 at 07:12 UTC. This page is informational and not investment advice.